1. Academic Validation
  2. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism

ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism

  • Nat Chem Biol. 2007 Nov;3(11):722-6. doi: 10.1038/nchembio.2007.34.
Lusong Luo 1 Cynthia A Parrish Neysa Nevins Dean E McNulty Amita M Chaudhari Jeffery D Carson Valery Sudakin Antony N Shaw Ruth Lehr Huizhen Zhao Sharon Sweitzer Latesh Lad Kenneth W Wood Roman Sakowicz Roland S Annan Pearl S Huang Jeffrey R Jackson Dashyant Dhanak Robert A Copeland Kurt R Auger
Affiliations

Affiliation

  • 1 Department of Enzymology and Mechanistic Pharmacology, Oncology CEDD, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA. lusong.luo@gsk.com
Abstract

The mitotic Kinesin KSP (Kinesin spindle protein, or Eg5) has an essential role in centrosome separation and formation of the bipolar mitotic spindle. Its exclusive involvement in the mitotic spindle of proliferating cells presents an opportunity for developing new Anticancer agents with reduced side effects relative to antimitotics that target tubulin. Ispinesib is an allosteric small-molecule KSP inhibitor in phase 2 clinical trials. Mutations that attenuate ispinesib binding to KSP have been identified, which highlights the need for inhibitors that target different binding sites. We describe a new class of selective KSP inhibitors that are active against ispinesib-resistant forms of KSP. These ATP-competitive KSP inhibitors do not bind in the nucleotide binding pocket. Cumulative data from generation of resistant cells, site-directed mutagenesis and photo-affinity labeling suggest that they compete with ATP binding via a novel allosteric mechanism.

Figures